The Centers for Medicare & Medicaid Services (CMS) has implemented a fundamental change to how Medicare reimburses skin substitute products, effective January 1, 2026. While framed as a payment reform, the policy change carries significant compliance and enforcement implications for wound care clinics, physicians, suppliers, and manufacturers.
For providers operating in the wound-care and regenerative medicine space, this change should be viewed as a warning sign of increased scrutiny and enforcement to come.
What Changed in Medicare Skin Substitute Reimbursement?
Under the Calendar Year (CY) 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F), CMS eliminated the long-standing practice of reimbursing most skin substitutes under the Average Sales Price (ASP) methodology.
New Rule (Effective January 1, 2026)
CMS now reimburses most skin substitute products as “incident-to supplies”, rather than as separately payable biologics.
This change applies to skin substitutes that are:
- Not licensed as biological products under Section 351 of the Public Health Service Act, and
- Previously reimbursed under Section 1847A of the Social Security Act using ASP-based pricing.
Products that are licensed under Section 351 (i.e., true biologics with a BLA) remain eligible for ASP reimbursement.
Why CMS Made This Change
CMS cited explosive growth in Medicare spending on skin substitutes, increasing from hundreds of millions of dollars annually to billions of dollars in recent years, particularly in the outpatient and physician office settings.
CMS expressed concern about:
- Rapid product proliferation
- Wide pricing disparities
- Utilization patterns inconsistent with clinical norms
- Financial incentives driving product selection rather than medical necessity
Rather than addressing these issues through coverage determinations alone, CMS chose to reset the payment structure entirely.
The New Payment Methodology Explained
CMS now groups skin substitutes into broad categories based on regulatory status (e.g., HCT/Ps and device classifications) and reimburses them using a blended supply-based payment rate tied to the application procedure.
Key Takeaway for Providers
There is no longer a direct link between a product’s acquisition cost and Medicare reimbursement for most skin substitutes.
This dramatically alters:
- Revenue models for wound-care clinics
- Physician compensation structures
- Manufacturer pricing strategy
Why This Signals Increased Enforcement Risk
From an enforcement perspective, payment reform often precedes fraud enforcement, not the other way around.
Historically, CMS reimbursement changes in areas with rapid spending growth (e.g., DME, genetic testing, telehealth) have been followed by:
- Targeted audits
- DOJ investigations
- False Claims Act litigation
Skin substitutes are now firmly in that category.
Likely Areas of Scrutiny
Providers should expect heightened focus on:
- Medical necessity for each application
- Frequency and volume of use
- Product selection rationale
- Documentation consistency
- Incident-to billing compliance
The HHS Office of Inspector General (OIG) has already flagged skin substitute billing as an area vulnerable to fraud, waste, and abuse, and CMS’s payment overhaul reinforces those concerns.
Compliance Risks Under the New Rule
Improper billing under the new framework may expose providers to:
- Overpayment demands and recoupments
- Civil Monetary Penalties (CMPs)
- False Claims Act liability
- Parallel criminal investigations in extreme cases
Importantly, billing a skin substitute as separately reimbursable when it no longer qualifies may be characterized as a false claim, even if the product was properly reimbursed under prior rules.
What Providers Should Do Now
Healthcare providers using skin substitutes should act proactively:
- Audit billing and coding practices immediately
- Update policies to reflect incident-to supply billing
- Strengthen medical necessity documentation
- Train clinicians and billing staff on the new rule
- Seek legal guidance when reimbursement questions arise
Early compliance intervention is often the difference between a manageable audit and a full-scale enforcement action.
Conclusion
CMS’s decision to fundamentally restructure skin substitute reimbursement is not merely about cost control. It reflects deep regulatory concern about utilization, pricing, and billing practices — and it strongly suggests that government enforcement will follow.
